HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SM Energy Company

http://sm-energy.com/

Latest From SM Energy Company

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Deals Asia Pacific

Earnings Winners & Losers: MMSI, STMN, WMGI, RWLK, EXAS

As the earnings season continues, Medtech Insight takes a look at dental firm Straumann’s performance, as well as that of some mid- to small-cap companies – including extremities implant specialist Wright Medical – highlighting which we believe to be the season’s winners and losers.

Sales & Earnings Companies

Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making

PwC anticipates a streamlining of the FDA approval process could address asset scarcity. AbbVie begins 2017 with three modest-sized deals, while PharmAthene and Altimmune join forces in a reverse-merger.

Deals M & A
See All

Company Information

  • Other Names / Subsidiaries
    • St. Mary Land & Exploration Co.
UsernamePublicRestriction

Register